Compare CII & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CII | PCRX |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 878.3M | 1.0B |
| IPO Year | N/A | 2010 |
| Metric | CII | PCRX |
|---|---|---|
| Price | $21.11 | $23.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $37.60 |
| AVG Volume (30 Days) | 75.7K | ★ 796.4K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 6.17% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.16 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | N/A | $7.10 |
| Revenue Next Year | N/A | $9.15 |
| P/E Ratio | ★ N/A | $146.94 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $15.20 | $18.80 |
| 52 Week High | $26.17 | $27.99 |
| Indicator | CII | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.95 | 57.50 |
| Support Level | $20.27 | $22.57 |
| Resistance Level | $21.43 | $23.91 |
| Average True Range (ATR) | 0.46 | 0.91 |
| MACD | -0.04 | 0.08 |
| Stochastic Oscillator | 0.00 | 80.61 |
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its investment objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. It may invest directly in such securities or synthetically through the use of derivatives. It also seeks to achieve its investment objective by employing a writing (selling) call and put options.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.